Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Brokerages
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus recommendation of “Buy” by the ...
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Here’s What Happened
Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares reached a new 52-week low during trading on Monday . The ...
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...
manilatimes18d
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...
Business Insider27d
Promising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis Treatment
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at $41.00. Pick the best stocks and maximize your ...
Morningstar17d
Oruka Therapeutics Inc ORKA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
U.S. News & World Report6mon
9 Short Squeeze Stocks That Could Take Off
The stock jumped in April 2024 after Arca announced a merger with Oruka Therapeutics, a private, clinical-stage biotech company focused on treating chronic skin diseases, including plaque psoriasis.
Business Insider18d
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for ...